Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI and poop analysis could revolutionize colon cancer screening

NCT ID NCT06174233

Diagnosis Sponsor: Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether analyzing the bacteria in stool samples with artificial intelligence can better predict colorectal cancer risk than the standard stool test. Researchers will collect samples from 2,500 people aged 50-75 who are already scheduled for a colonoscopy. The goal is to see if this new method can more accurately identify who truly needs a colonoscopy, potentially reducing unnecessary procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a more accurate, non-invasive screening test for colorectal cancer, reducing unnecessary colonoscopies.
What could go wrong
This is an observational study, not a treatment trial. The new test may not prove more accurate than current methods, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients aged between 50 and 75 scheduled for colonoscopy as part of routine care.

Ages

50 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Between the ages of 50 and 75 * Requiring colonoscopy * Able to provide a faecal sample and to perform a FIT test prior to colonoscopy * Without known inflammatory bowel disease (chronic inflammatory bowel disease (IBD), chronic ulcerative colitis (CUC) and Crohn's disease (CD)) * No medical condition that, in the opinion of the investigator, should preclude inclusion in the study * Not having participated in any other clinical research study in which an investigational drug has been administered within 60 days prior to and including the date of informed consent or is likely to be administered during the period of colonoscopy * Participation agreement signed electronically Exclusion Criteria: * Persons not living in France (declaratory); * Persons subject to a protective measure, in particular guardianship or trusteeship, or unable to express their consent (declarative); * Persons who have had a colectomy (declaratory); * Person with a digestive stoma (declaration); * Person who did not sign the consent form; * Person who did not answer the entry questionnaire; * Person who did not send a compliant stool sample; * Antibiotics taken in the 3 months prior to inclusion (self-report); * Person aged under 50 or over 75.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adenoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adenoma colorectal adenoma colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Patients aged 50-75 and requiring colonoscopy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hopital Avicenne, Centre de Recherche sur Volontaire

    RECRUITING

    Bobigny, 93000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.